EMA Application withdrawn: Ratioepo (epoetin theta) — Ratiopharm GmbH

View source ↗

Summary

EMA withdrew the application for Ratioepo (epoetin theta) by Ratiopharm GmbH for anemia-related indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Cancer
• Kidney Failure

Drugs mentioned

• Ratioepo (epoetin theta)

Snippet

Status: Application withdrawn. Therapeutic area: Anemia;Kidney Failure;Cancer. MAH: Ratiopharm GmbH. Decision date: 26/04/2010